BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally.
This drug is currently being used in treatment for other cancers in research studies and
information from those other research studies suggests that this agent, BIBF 1120, may help
to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth
of new blood vessels at the site of the tumor. In this research study, the investigators are
looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Boehringer Ingelheim Massachusetts General Hospital The Cleveland Clinic University of Virginia Wake Forest Baptist Health Wake Forest University Health Sciences